Infinity Pharmaceuticals Inc. (NASDAQ:INFI) announced that clinical data from its IPI-549 Phase 1/1b study was selected as a late-breaking abstract and will be presented on …
In a research report issued today, Wedbush analyst David Nierengarten reiterated a Neutral rating on Infinity Pharma (NASDAQ:INFI) with a $15 price target, …
In a research report issued today, William Blair analyst Y Katherine Xu assigned an Outperform rating on Infinity Pharmaceuticals (NASDAQ:INFI) with a price target …
